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Abstract 
 
Atopic dermatitis is a worldwide prevalent chronic inflammatory skin disease, 
affecting predominantly children, although it may persist into adulthood. Pruritic 
eczematous lesions with age-related morphology and distribution are a central feature 
of the disease which, along with other symptoms, seriously affect patients’ quality of life. 
Both immune dysregulation and cutaneous barrier dysfunction are involved in the 
pathophysiology of the disease, although the exact mechanisms are still unclear. The 
concept of atopic dermatitis as a biphasic Th1-Th2 disease is changing, as recent 
evidence supports systemic activation of multiple other Th-cells subsets. 
Atopic dermatitis has been associated with an increasing number of comorbidities, 
possibly sharing some common pathological mechanisms. The atopic march is well 
known and represents the natural progression of atopic diseases in a considerable 
number of patients, usually starting with the development of atopic dermatitis followed 
by other atopic conditions, such as asthma and allergic rhinitis. Association of atopic 
dermatitis with cardiovascular disease, autoimmune diseases, as well as cutaneous and 
extracutaneous infections have been increasingly reported, although the link is not yet 
clear, requiring more research. Furthermore, the association between atopic dermatitis 
and neuropsychiatric conditions has also been widely studied, with the increased risk of 
mental health disorders being strongly influenced by sleep disorders, which are also 
prevalent among these individuals. 
Altogether, these associations contribute to the burden of atopic dermatitis, which 
increases the need of a closer and multidisciplinary approach of the patients, regarding 
the best control of their skin disease, along with prevention or early diagnosis and 
treatment of the comorbidities that may arise. 
This review explores the recent associations with atopic dermatitis and the 
possible underlying mechanisms involved, which supports the concept of atopic 
dermatitis as a systemic disease. 
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Resumo 
 
A dermatite atópica trata-se de uma doença cutânea inflamatória crónica 
prevalente em todo o mundo, que afeta principalmente crianças mas que pode persistir 
na idade adulta. As lesões eczematosas pruriginosas são uma característica central da 
doença que, juntamente com os outros sintomas, afetam gravemente a qualidade de 
vida dos pacientes. A fisiopatologia da doença envolve uma desregulação imune e uma 
disfunção da barreira cutânea, no entanto os mecanismos exatos ainda não estão 
totalmente claros. O conceito de dermatite atópica como uma doença bifásica Th1-Th2 
tem sido desafiado, uma vez que evidências recentes enfatizam uma ativação sistémica 
de múltiplos grupos de células Th. 
A dermatite atópica tem sido associada a um número crescente de 
comorbilidades que possivelmente partilham alguns mecanismos patológicos. A marcha 
atópica é bem conhecida e representa a progressão natural das doenças atópicas num 
número significativo de pacientes, geralmente sendo iniciada pelo desenvolvimento da 
dermatite atópica, seguida por outras condições atópicas, como a asma e a rinite 
alérgica. A associação da dermatite atópica com doenças cardiovasculares, autoimunes, 
assim como com infeções cutâneas e extracutâneas tem sido cada vez mais 
demonstrada, apesar da sua relação ainda não ser clara, exigindo mais estudos. Além 
disso, a associação entre dermatite atópica e distúrbios neuropsiquiátricos também tem 
sido largamente estudada, sendo que o risco aumentado de doença mental é fortemente 
influenciado pelas perturbações do sono, que também são prevalentes nestes 
indivíduos. 
No seu conjunto, estas associações contribuem para o impacto negativo da 
dermatite atópica, aumentando a necessidade de uma abordagem mais próxima e 
multidisciplinar dos pacientes, tendo em vista o melhor controlo da sua doença cutânea, 
assim como a prevenção ou diagnóstico precoce e tratamento das comorbilidades que 
possam surgir. 
Esta revisão bibliográfica explora as associações mais recentes da dermatite 
atópica e os possíveis mecanismos subjacentes envolvidos, que apoiam o conceito de 
dermatite atópica como uma doença sistémica. 
 
 
Palavras-chave: dermatite atópica; comorbilidade; doenças autoimunes; doenças 
cardiovasculares; infeção; doenças mentais. 
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Introduction 
  
Atopic dermatitis (AD) is a common chronic inflammatory skin disorder affecting 
up to a fifth of the population in developed countries.1 The prevalence of the disease is 
higher among children, but many continue to be affected during adulthood.2 
AD has a complex pathogenesis which includes barrier dysfunction and immune 
dysregulation that is driven by interactions of genetic and environmental factors.3 The 
abnormal cutaneous barrier facilitates the exposure to environmental allergens, with the 
subsequent activation of the immune system, resulting in the development of the 
inflammatory cascade of atopic disease.3 The immune profile in AD is complex and, 
although it has been considered a biphasic T helper (Th) 2/Th1 mediated disease, recent 
studies have suggested that patients with AD also show Th22 and Th17 activation.4 
Filaggrin (FLG) is a structural protein of the cutaneous barrier and mutations in the FLG 
gene are associated with an increased risk of AD (with more than 40% of all carriers 
affected), asthma, allergic rhinitis, contact allergy and peanut allergy.5 FLG deficiency is 
associated with early AD onset, severe disease, greater allergic sensitization and higher 
incidence of skin infections with herpes virus.6 FLG mutations also seem to play a role 
for disease persistence, as well as early onset of AD and the existence of atopic 
comorbidities.7,8 
The diagnosis of AD relies on clinical features. Essential features are pruritus and 
eczematous lesions, with age-related morphology and distribution, usually affecting 
extensor surfaces of the body and face during the infantile phase, shifting to flexural 
surfaces in childhood and later to the hands, head and neck in adults.1,8 Other 
dermatological signs and symptoms of AD include xerosis, lichenification and prurigo-
like nodules.1 Altogether, the AD manifestations contribute toward deep disturbances on 
the physical and psychosocial wellbeing of patients, negatively affecting their quality of 
life.8 
AD has long been closely associated with other atopic disorders, however recent 
studies have suggested multiple other associations, such as cardiovascular diseases 
(CVD), autoimmunity/inflammatory diseases, infections, neuro-psychiatric disorders, 
among others, some of which are more controversial than the rest. For this reason, the 
concept of AD as a systemic disease is gaining strength, along with a greater need for 
data on the comorbidity profile of patients with AD. 
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Objectives and Methods 
  
The purpose of this review is to explore the recent developments in the immune 
profile and comorbidities of AD which suggest that it is not only a dermatological 
condition but also a systemic disease. 
The research for this review included studies published from 2007 to 2017 and 
written in English, searched through PubMed and Science Direct using the keywords 
atopic dermatitis/atopic eczema exclusively and combined with comorbidity, 
autoimmunity, inflammatory diseases, cardiovascular, infection and mental health 
disorders. 
Only original studies were considered, with the exception of two review articles 
that were used to assess solid concepts related to AD prevalence, pathophysiology, 
signs and symptoms, and one metaanalysis due to its relevance. Studies were included 
based on the title or abstract if they were investigating the immune alterations of AD, the 
association between AD and other diseases/comorbidities or the possibility of AD being 
a systemic disease. Furthermore, some studies were rejected after their full-text analysis 
in case they did not meet the objective of this review, if not yet excluded based on the 
above-mentioned criteria. Additionally, some articles cited in the selected publications 
were included in the analysis.  
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The atopic march 
  
AD is often accompanied by other atopic diseases, and it is usually the first step 
of the so-called atopic march9, given that the dysregulated epidermal barrier facilitates 
allergenic sensitization10, with the subsequent onset of other conditions such as allergic 
rhinitis and asthma or even food allergy and allergic conjunctivitis.9 
AD is traditionally divided in extrinsic and intrinsic sub-types, comprising 
approximately 80% and 20% of atopic patients, respectively.11 The first form of AD is 
usually characterized by elevated serum immunoglobulin (Ig) E, often with a positive 
personal and familial history of atopy and specific IgEs to allergens; the second and less 
common form, although phenotypically identical, does not show high serum IgE, 
sensitization to specific allergens or other atopic comorbidities.11 Nevertheless, those 
definitions have been challenged by recent findings. Pinart et al.12 used data from a large 
network of longitudinal birth cohorts in 8 European countries, the Mechanisms of the 
Development of ALLergy (MeDALL) project, to investigate the excess atopic comorbidity 
of eczema, allergic rhinitis and asthma and its modification by IgE sensitization, in 
children at 4 and 8 years of age. The comorbidity of two or three of those atopic 
conditions exceeded the expected by chance alone (if the diseases were independent). 
They found a greater absolute excess comorbidity in children with IgE sensitization than 
in those without, however the excess comorbidity was also demonstrated in children 
without IgE sensitization. Also, the presence of IgE sensitization at age 4 years 
independently increased the relative risk of comorbidity at age 8 years, which supports 
the role of IgE sensitization in comorbidity. On the other hand, stratifying by IgE 
sensitization, the relative risk of comorbidity was stronger in children without serum-
specific IgE, questioning the dominant role of IgE sensitization in atopic comorbidity. 
Ultimately, the researchers showed that only 38% of the incidence of comorbidity at age 
8 years was due to IgE sensitization, so additional studies should be warranted to assess 
the mechanisms involved in this excess of comorbidity. 
Since it is unclear why only a part of patients with AD develop other atopic 
diseases, Wan and colleagues13 aimed to assess the role of the age of AD onset on the 
risk for asthma and seasonal allergies in a cohort study. They found a higher prevalence 
of both atopic diseases in patients in the early AD onset group (before 2 years of age) 
than in mid- and late-onset groups (3 to 7 and 8 to 17 years, respectively). The risk for 
development of seasonal allergies significantly decreased as the age of AD onset 
increased, but the same was not true to asthma. Hence, the timing of AD onset may 
explain the variation in the atopic march, but only partially. Furthermore, FLG mutations 
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also play a role in the AD associated atopic diseases, as AD carriers of those mutations 
have an increased risk of asthma.10 
The AD onset before 2 years of age also appears to be an important factor on 
the persistence of the disease in adulthood, along with childhood hand eczema and 
comorbid allergic rhinitis, in contrast with asthma and allergic contact dermatitis during 
childhood, which were not significant risk factors for the maintenance of the disease in a 
study conducted by Mortz et al.8 
 Although atopic comorbidities are the most established associations of AD, the 
study of these associations in order to find the underlying causal mechanisms appears 
to be far from over. 
 
 
Systemic immune activation in Atopic Dermatitis 
  
There are increasing evidences for systemic immune activation in AD. Cytometry 
studies have shown that moderate-to-severe AD patients have increased activated T-
cell subsets in blood compared to controls,14,15 and at even higher frequencies than in 
patients with psoriasis.14 Also, pathologic T-cell activation extends into skin-homing and 
central memory populations.14 
A recent study16 involving moderate-to-severe AD patients looked for new 
biomarkers that would correlate with AD severity, assessed with Scoring of AD 
(SCORAD), and with an epidermal hyperplasia score (thickness and K16 mRNA), before 
and after Cyclosporine A treatment. These researchers found that AD patients had 
increased serum cytokines and chemokines compared to controls, which were reduced 
with treatment, and they also found that SCORAD correlated with immune and epidermal 
measures in lesional, and even more strongly in non-lesional skin.  
Another study17 compared the AD profile of serum inflammatory mediators to 
patients with psoriasis and there were large differences between AD and psoriasis blood 
signature, with more immune pathways showing stronger activation in AD patients (e.g. 
cytokine-cytokine receptor interaction, chemokine signaling pathway, cytokines and 
inflammatory response, dendritic cell pathway, Th1/Th2 differentiation). It was found 
increased Th1, Th2, Th17/Th22 and Th1/Th17/Th22 products in the blood of AD patients 
and, additionally, several inflammatory mediators from all T-helper-cells axes correlated 
with lesional and non-lesional skin. Indeed, in another recent study,11 both intrinsic and 
extrinsic forms of AD showed significant increases in gene expression levels of Th2 and 
Th1 cytokines in lesional and non-lesional skin, although lesional skin in intrinsic AD 
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showed significantly more robust Th22 and Th17 immune responses compared to 
extrinsic AD.  
Vekaria et al.18 conducted a retrospective study and showed that AD patients had 
significantly increased blood C-reactive protein (CRP) levels, an acute phase reactant 
whose levels rise in response to systemic inflammation, compared to controls. Even after 
they excluded all patients with a history of asthma, a disease associated with increased 
CRP serum levels, differences remained significantly higher. Interestingly, in this study, 
they also demonstrated a correlation between AD severity and CRP levels.  
Altogether, these findings reflect the strong immune activation in AD and 
highlights the systemic abnormalities of AD beyond the skin and allergic associations. 
 
 
Autoimmune and inflammatory diseases 
  
Accumulating evidence suggests an association between AD and a variety of 
autoimmune diseases. Andersen et al.19 examined the co-occurrence of 22 autoimmune 
diseases in adults with AD and showed that AD was significantly associated with 11 of 
those diseases, wherein patients with a history of smoking had a significantly higher risk.  
Vitiligo and alopecia areata (AA) are autoimmune disorders that have been 
associated with AD. Vitiligo is characterized by melanocyte destruction which leads to 
loss of pigmentation. Silverberg and Silverberg20 found a significantly increased 
prevalence of AD in patients with vitiligo involving a body surface area of at least 76% 
and itching or burning of skin, compared to the general population. The authors 
suggested that the pro-inflammatory status of AD may lead to melanocyte destruction 
and that there may be a common genetic mutation which predisposes to both AD and 
vitiligo. Furthermore, Augustin et al.21 reported that vitiligo was seen 3.3 times as often 
in children with AD than in control subjects, and as well that the prevalence of AA was 
significantly higher in children with AD than in non-AD children.  
A self-reported history of atopy, particularly AD, was associated with an increased 
risk of AA in a case-control study with 2055 patients with AA and 558 controls.22 
Moreover, FLG mutations are more frequent among AA patients with a history of AD and, 
in that case, the clinical presentation of AA may be more severe, which suggests that an 
epidermal barrier defect contributes to a severe course of AA.23 
Systemic lupus erythematosus (SLE) is another autoimmune disease that has 
been associated with AD.19,24-26 A Taiwanese study24 found that patients with AD have a 
significantly higher risk of SLE compared to healthy controls. The researchers also found 
that female AD patients and juvenile patients with AD younger than 18 years old had an 
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increased risk of SLE in relation to male AD patients and adult patients with AD, 
respectively. Th2 response is predominant in SLE and is also part of the AD 
pathogenesis, therefore SLE and AD share similar immune dysfunction, suggesting that 
these dysregulations and the overproduction of inflammatory mediators may have a role 
for the increased risk of SLE in patients with AD.24 
Using The National Health Insurance Research Database of Taiwan, Wei et al.25 
conducted a retrospective cohort study in which they compared 192,357 AD patients with 
769,428 non-AD controls aged under 18. The incidence of juvenile SLE was 2.90-fold 
greater in the AD group than in the non-AD subjects and the incidence rates of SLE were 
higher for girls than for boys. In addition, a study26 showed that SLE subjects had more 
atopic disease comorbidities compared to the control group, especially AD but also 
allergic rhinitis, allergic conjunctivitis and asthma and, again, this was particularly 
observed for female patients.  
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the 
gastrointestinal tract caused by an abnormal activity of the immune system, with its main 
forms being Crohn’s disease (CD) and ulcerative colitis (UC).27 A recent Danish study19 
comparing 8,112 adults with a diagnosis of AD with 40,560 age- and sex-matched 
controls reported that AD was significantly associated with both CD (aOR 2.09; 95% CI: 
1.52-2.85) and UC (aOR 1.64; 95% CI: 1.31-2.05). Additionally, another study21 
demonstrated that the prevalence of UC among children affected with AD is significantly 
higher than among controls, however, even though they found a greater prevalence of 
CD in the patients group, this association was not statistically significant.  
A retrospective cohort study28 used data from German National Health Insurance 
beneficiaries aged 40 or younger, including 49,847 individuals classified as having 
prevalent AD and 605,968 non-AD subjects. The researchers found that patients with 
AD were at increased risk for incident IBD, including CD (RR 1.34; 95% CI: 1.11-1.61) 
and UC (RR 1.25; 95% CI: 1.03-1.53). They also explored established IBD loci in high-
density genotyping data from 2,425 patients with AD and 5,449 controls, but they did not 
find a higher proportion of risk alleles for IBD associated with AD in a consistent 
directionality more frequently than the 50% expected by chance. Nevertheless, one UC 
locus and four CD risk loci were significantly associated with AD, including important 
genes for adaptive immune regulation and tissue response. 
A South Korean cross-sectional study27 assessed the risk of patients with IBD 
developing inflammatory skin diseases, comprising AD, psoriasis and rosacea. After 
adjusting for age and sex, the authors reported that patients with IBD were at an 
increased risk of AD, compared to control subjects. Th17-mediated inflammation is 
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important in the pathogenesis of IBD27 and increasing evidences suggest that Th17 cells 
are also involved in the pathogenesis of AD.17,27 
Celiac disease is a childhood immune-mediated disease of the small intestine in 
which the ingestion of products with gluten causes chronic inflammation and damage of 
the mucosa.29 Atopy has been found frequently in individuals with celiac disease in 
previous studies so, recently, Ress et al.29 studied a sample of 351 Estonian children 
with active AD and found a 4-times greater prevalence of celiac disease than in randomly 
selected schoolchildren. They also found that AD patients can present an atypical or 
silent celiac disease, although with important histological features. 
This apparent increased risk of autoimmune/inflammatory diseases in AD 
patients may be due to similarities in the genetic susceptibilities and immune activation, 
yet it is not possible to make conclusions about causality based on observational data. 
In any case, physicians accompanying AD patients should increase awareness of 
autoimmune comorbidities in those patients. 
 
 
Cardiovascular risk and disease 
  
Recent studies have suggested an association between AD and cardiovascular 
risk factors (CVRF) and disease. Patients with AD are more likely to have CVRF such 
as sedentary lifestyle, performing less vigorous physical activity, increased alcohol and 
cigarette consumption30,31, obesity30,32,33, high blood pressure30,33 and high cholesterol30. 
Zhang and Silverberg32 performed a meta-analysis of 30 observational studies to 
examine the relationship between AD and overweight/obesity and they concluded that 
there is a significant association in North America and Asia, where children and adults 
with AD present a higher prevalence of overweight and obesity than the general 
population, but the same was not observed in Europe. Also, a case-control study33 
performed in multicenter pediatric dermatology practices in the United States (US) 
suggests that moderate to severe AD in children may be associated with central obesity 
and increased systolic blood pressure. 
A Taiwanese study34 using a national database demonstrated that patients with 
AD had a higher risk of ischemic stroke and, even after adjusting for age, sex, 
comorbidities, and medications, patients with AD had a 1.33-fold increased incidence, 
suggesting that AD is an independent risk factor for ischemic stroke. Additionally, they 
showed a correlation between the severity of the disease and the risk of ischemic stroke, 
with severe forms of the skin condition presenting a higher risk than mild or moderate 
forms. 
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Using Cardiac Computed Tomography Angiography, Hjuler et al.35 showed an 
increased coronary artery calcium score of the coronary vessels and mild single-vessel 
disease in adults with AD without known CVD. Moreover, the prevalence of coronary 
artery disease (CAD) appears to increase in subjects with severe and persistent AD, so 
these findings indicate that AD might be associated with a higher risk of CAD.35 
In a US National Health and Nutrition Examination Survey (2005-2006), using 
multi-variate models that controlled for socio-demographic factors, asthma and allergic 
rhinitis, flexural eczema was associated with significantly increased odds of CAD, heart 
attack and congestive heart failure, although the same association was not found with 
stroke.36 In models that controlled for CVRF, only the association between eczema and 
CAD remained significant. Likewise, in two US National Health Interview Surveys (2010 
and 2012), 1-year history of eczema was associated with significantly higher odds of 
CAD, angina, heart attack, other heart disease, stroke and peripheral vascular disease 
in multivariate models.36 
Nevertheless, contradictory findings about the association between AD and CVD 
are rising. A Danish study37 comprising a total of 26,898 mild and 2,527 severe cases of 
AD and 145,372 control subjects, initially found an increased risk of CVD in AD patients, 
however, after adjusting for socioeconomic status, smoking, medication, and 
comorbidities the increased risk was no longer present. So, this higher incidence of 
adverse cardiovascular outcomes seems to be explained by an increased burden of 
comorbidities and harmful life behaviors. Indeed, a study that assessed the major 
comorbidities38, and not only CVD, in adults with AD using the Charlson comorbidity 
index, showed that the risk for important comorbidities was significantly increased in 
patients with AD compared to non-AD controls and this risk difference was especially 
found in subjects with severe disease and, again, among smokers.  
Although Silverberg and Greenland30 found that adults with eczema had higher 
rates of prediabetes and diabetes, another study31 demonstrated a lower prevalence of 
type 2 diabetes in patients with AD than in psoriasis patients, as well as in controls. 
In fact, newer studies are suggesting that AD is not an independent risk factor for 
CVD. Drucker et al.39 conducted a cross-sectional analysis from a large Canadian cohort 
and, in contrast to the above-mentioned studies, found that AD was inversely associated 
with hypertension (OR 0.87; 95% CI: 0.83-0.90), type 2 diabetes (OR 0.78; 95% CI: 0.71-
0.84), myocardial infarction (MI) (OR 0.87; 95% CI: 0.75-1.00) and stroke (OR 0.79; 95% 
CI: 0.66-0.95). Besides that, in a cohort of American women40, AD was not independently 
associated with non-fatal MI or stroke, after controlling for important mediators of CVD.  
Longitudinal analysis of AD patients in the German AOK PLUS cohort41 showed 
a weak association between AD and the development of hypertension, angina pectoris 
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and peripheral arterial disease, but not for MI and stroke. Furthermore, in the same study, 
the authors did not find robust evidence for shared genetic risk variants of AD and CVD.  
Marshal et al.42 aimed to determine whether three major inflammatory 
dermatologic diseases, namely AD, psoriasis and rosacea, were independent risk factors 
for CVD 1-year following diagnosis. Comparing with controls, the adjusted odds of 
cardiovascular outcomes were not higher in patients with any of the three conditions.  
Although there are contradictory results, altogether these findings suggest that 
rather than the systemic inflammation associated with AD, it is possible that increased 
CVRF and poor health behaviors, such as smoking, drinking alcohol or being sedentary, 
are important factors for cardiovascular events. Patients should be encouraged to modify 
those habits and acquiring a healthier lifestyle. 
 
 
Cutaneous and extra-cutaneous infections 
  
Patients with AD are more susceptible to multiple cutaneous bacterial, viral and 
fungal infections than the general population.43 The infection with Staphylococcus aureus 
(SA) is one of the most common complications of AD43 because this bacteria, which is a 
colonizer of the skin microbiota, can become pathogenic under certain conditions, such 
as the loss of integrity of the skin barrier.44 Healthy individuals show SA colonization 
prevalence of 5–30%44, which are lower than those observed in AD patients. Suh et al.45 
performed a cross-sectional study comprising 54 patients with AD aged from 3 months 
to 17 years, and reported that 80% of those patients were colonized with SA, while 13% 
of the total number, or 16% of those colonized with SA, were carriers of Methicillin-
Resistant SA (MRSA), with previous hospitalization being independently associated with 
MRSA colonization. The concomitant use of topical calcineurin inhibitors and topical 
steroids was associated with SA and MRSA colonization, with the patients who used that 
combination being significantly more likely to be colonized than patients who used 
exclusively topical steroids. On the other hand, the use of topical antibiotics was 
associated with reduced SA colonization, whereby its use appears to be a protective 
factor.  
 A high rate of SA colonization was also reported in a Canadian cross-sectional 
study43 of lesional skin and nares swabs from 200 pediatric patients with AD, in which 
61.5% were carriers, represented by 43.7% of skin swabs and 48% of nares swabs. In 
this study, SA colonization was more frequent in older patients and in those with higher 
disease severity scores. Although, in contrast to the last mentioned study, only one of 
the isolations represented MRSA. Furthermore, the results of a Brazilian study44 confirm 
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a high rate of SA colonization in children with AD and suggest an important association 
between colonization and severity of the disease, in this case assessed using the 
Eczema Area and Severity Index (EASI) score. Of the patients sampled, 73.6% were 
carriers of SA, nasal swabs were positive in 60.4%, lesional skin swabs were positive in 
48.4%, and both lesional skin and nasal swabs were positive in 35.2%. However, no 
MRSA was found in cultures from any of the subjects. 
The loss of integrity of the cutaneous barrier seen in AD leads to a greater 
susceptibility of the stratum corneum to the SA colonization, which explains the observed 
high rates of carriers.43 This bacteria produces toxins that act as superantigens and 
maintains skin inflammation, eliciting a strong immune response.43 
Impetigo contagiosum (IC) is caused by the inoculation of SA or group A 
streptococci into superficial sites of minor trauma, instead of intact skin, and it is a 
common infection in children with AD.46 Hayashida et al.46 reported a greater prevalence 
of personal and familial AD history in pediatric patients with IC compared with children 
without this infection, with the odds of a history of IC being 1.8 times higher in AD patients 
than in non-AD patients. The authors suggested the dysfunction of the skin barrier, small 
traumas due to scratching, bacterial colonization of the skin, especially SA, and 
decreased levels of antimicrobial peptides in the skin as possible responsible factors for 
the high lifetime prevalence of IC in AD.  
A subgroup of patients with AD are also susceptible to serious viral infections. 
The most frequent viral complication in subjects with AD is eczema herpeticum (EH), 
which is a severe and extensive viral superinfection caused by herpes simplex virus 
(HSV) on eczematous skin lesions, occurring most frequently in the second and third 
decade of life.47 This condition is designated as AD complicated by EH (ADEH) and 
sometimes it can be complicated by keratoconjunctivitis, which can result in blindness, 
viremia and multiple organ involvement with meningoencephalitis.48,49 
Beck et al.48 compared AD patients with history of EH (ADEH+) with AD patients 
without history of EH (ADEH-) and healthy controls to characterize those patients who 
are more prone to develop EH. The ADEH+ subjects had greater severity of AD 
(evaluated using EASI and Rajka-Langeland scores), a higher affected body surface 
area, were more likely to have a history of other allergic conditions, were more often 
sensitized to many common allergens than ADEH- patients and presented higher levels 
of serum IgE. Additionally, the ADEH+ group more often had a history of cutaneous 
infections with SA and Molluscum contagiosum virus (MCV) and also a history of HSV 
infection of the eye than both the ADEH- and control groups. Besides the more 
pronounced sensitization to aeroallergens and higher levels of serum IgE in the ADEH+ 
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patients, Peng et al.47 also found that the ADEH+ group had a greater prevalence of early 
age onset of AD along with a persistent and recurrent course of AD until adulthood.  
A feature of ADEH+ patients is their Th2 predominance and relative Th1 
deficiency.47,48 AD patients with EH have more Th2-polarized disease demonstrated by 
their higher serum levels of the Th2 chemokine TARC/CCL17, their greater peripheral 
eosinophilia and greater allergen sensitization compared to ADEH-.48 This Th2/Th1 
imbalance leads to the decreased production of antimicrobial factors and reduced 
cutaneous barrier proteins,48 and the defect in epidermal barrier and immune responses 
to pathogens may be important for viral and bacterial infections of the skin. Moreover, 
IFN-γ-producing cells are important cytotoxic effectors of immune system against viruses, 
however the ADEH+ patients present reduced IFN-γ production and downregulation of 
IFN-γ receptor compared to ADEH- and non-atopic control subjects.50 
 Loss-of-function null mutations R501X and 2282del4 in the FLG gene have been 
consistently associated with risk of AD, representing the strongest genetic risk factors 
for AD.49 The R501X mutation confers an added risk of ADEH among European 
American patients and African American patients, however the association between the 
2282del4 mutation and ADEH was only significant among European American patients, 
while it was absent in the ADEH+ African American patients.49 Moreover, the combined 
R501X and 2282del4 mutations further increased the association for AD and ADEH. 
MCV belongs to the poxvirus family and replicates in keratinocytes leading to a 
disruption in the keratinization process.51 An Italian study51 involving 100 children with 
AD and 97 controls revealed that the presence of mutations in the FLG gene was also 
associated with a significantly increased risk of MCV skin infection, as well with an early 
onset of AD and more severe clinical course of the disease, given that AD patients with 
specific FLG variants were predisposed to moderate and severe SCORAD scores. 
Therefore, the loss of FLG gene function leads to a defective skin barrier, allowing the 
penetration of antigens and increasing the susceptibility to skin infection. 
Beck and colleagues48 reported that Human papilloma virus (HPV) infections 
were more frequent in AD patients compared with the non-AD control group. Likewise, 
Silverberg and Silverberg52 performed a study using the US 2007 National Health 
Interview Survey and found higher odds of warts (cutaneous infection with HPV) in 
children with AD and other concomitant atopic disease. In the same study, the 
researchers demonstrated that AD children with or without atopic comorbidities were 
associated with higher odds of various extracutaneous infections, namely strep throat, 
other sore throat, head or chest cold, influenza/pneumonia, sinus infections, recurrent 
ear infections, varicella and urinary tract infections. Moreover, Strom and Silverberg53 
used the US 2012 National Health Interview Survey to analyze whether adult AD was 
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also associated with diverse extra-cutaneous infections. In fact, they showed that adult 
AD was significantly associated with increased odds of infectious diseases/immune 
conditions, fever lasting more than 24 hours as well as all the same extracutaneous 
infections abovementioned for children with AD, with the exception of recurrent ear 
infections and urinary tract infections. Adult AD alone was significantly associated with 
one, two, three and even more strongly with four or more infections; AD with atopic 
disease was associated with even higher risk of two, three and four or more infections 
compared to AD alone.  
Frankowska et al.54 conducted a retrospective analysis of the medical 
documentation of a group of children born between 2005 and 2008 treated in the 
Outpatient Clinic of the Polish Mother’s Memorial Hospital in Lodz, consisting in 116 
infants and small children with AD and 136 children without atopy included in the control 
group, and showed that lower respiratory infections (pneumonia and bronchitis) were 
significantly more frequent in the AD group. Additionally, children with AD were more 
often hospitalized, especially due to pneumonia and spastic bronchitis. Using the same 
sample as the last-mentioned study, Rotsztejn et al.55 reported a higher occurrence of 
episodes of diarrheas and/or vomiting in children with AD, with a total percentage of 
positive stool culture significantly higher in children with AD compared to the control 
group (34.6% vs 17.6%, respectively, p<0.001). SA was the most common pathogen 
cultured in stools, with every fifth child with AD having positive cultures for SA, but 
Candida strains were also frequent in the group of AD children. Also, children with AD 
more often manifested chronic diarrhea and required antibiotic therapy.  
Hence, the association between AD and multiple cutaneous and extracutaneous 
infections supports the potential role of immune dysregulation in pathogenesis of AD. 
Since these infections can be serious, fatal or cause sequelae for the rest of patients’ 
lives, physicians should be aware of them and provide educational information to patients 
in order to prevent those infections. 
 
 
Sleep disturbances and mental health disorders 
  
AD has long been associated with sleeping problems and poor quality of sleep, 
as well as with a variety of mental health disorders. 
Pruritus is a central symptom in this inflammatory cutaneous disease and has an 
important impact on sleep.56-58 Using polysomnography and actigraphy, Bender et al.56 
demonstrated that sleep quality decreased as the severity of the disease increased in 
adult patients with AD, with greater disease severity being highly associated with more 
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scratching and poorer sleep. These researchers suggested that the psychologic distress 
related to AD may result from the impaired sleep, which in turn impairs daytime 
functionality. Indeed, in another study,57 adults with eczema had a higher prevalence of 
fatigue, regular daytime sleepiness and regular insomnia, which are significant mediators 
of poorer overall health status, higher number of sick days and doctor visits.  
Sleep impairment due to pruritus is also an important problem in children suffering 
from AD, predicting emotional and conduct disorders.58 On the other hand, eczema 
without concurrent sleeping problems did not increase the risk of mental health disorders, 
suggesting that sleeping problems play a central role for the development of the 
psychopathologies associated with AD.58 
A case-control German study59 with 3769 AD patients aged 15 or older found that 
adult eczema was independently associated with major psychiatric and psychosomatic 
disorders, namely schizophrenic, affective, neurotic, stress-related, somatoform, 
personality and behaviour disorders. Besides that, the likelihood of being affected by any 
of those conditions significantly increased with each physician visit due to AD.  
Yaghmaie et al.60 also found a strong association between multiple mental health 
disorders and AD, this time in the US pediatric population, and this association is further 
enhanced as the severity of the AD increases. Furthermore, a more recent population-
based longitudinal cohort study in South Korea61 demonstrated that subjects with AD 
diagnosis aged 20 or younger were significantly more likely of visiting a psychiatrist for 
all psychiatric disorders and this risk increased as the complexity of their treatment 
regimen raised.  
 The prevalence of both moderate and severe depression was higher in US adults 
with AD compared to controls, in a study using data from the US 2005-2006 National 
Health and Nutrition Examination Survey and 2012 National Health Interview Survey.62 
This results are in line with a previous large Korean study63 which showed a greater 
prevalence of depressive symptoms in adults with AD relatively to that of control subjects.  
A Taiwanese prospective cohort study reported that both adults and adolescents 
suffering from AD were more prone to developing major depression, any depressive 
disorder and anxiety disorders than the non-AD group during the follow-up period, even 
after adjusting for other atopic comorbidities64, which are also associated with sleep 
disturbance and cognitive dysfunction65. Adolescents with AD are more likely to 
experience depressive feelings, suicide ideation, suicide planning and suicide attempts 
than non-AD subjects.66 Moreover, the results from a study conducted by Halvorsen et 
al.67 revealed that 15.5% of the adolescents with AD reported suicidal ideation, 
contrasting with only 9.1% of the control group. The prevalence was even greater when 
they analyzed the patients with both eczema and pruritus, reaching 23.8%. 
14 
 
Atopic diseases have been associated with Attention Deficit/Hyperactivity 
Disorder (ADHD),65,68-72 the most frequent psychiatric disorder in childhood68, and Autism 
Spectrum Disorders (ASD)69,72, however contradictory results have been found. Chen et 
al.69 conducted a prospective longitudinal study involving an atopic cohort, aged under 3 
and born between 1997 and 2000, comprising 14,812 atopic patients with any atopic 
disease diagnosis without a proper discrimination (asthma, AD, allergic rhinitis or allergic 
conjunctivitis), and a non-atopic cohort with 6944 subjects. The participants were 
followed until the end of 2010 to compare the development of ADHD and ASD, which 
achieved a significant superior risk in the atopic group, with hazard ratios (HR) of 1.97 
(95% CI: 1.69–2.29) and 3.40 (95% CI: 1.95–5.93), for ADHD and ASD, respectively. 
The risk of developing any of these psychiatric disorders showed a dose-dependent 
relationship, increasing with the number of concurrent atopic diseases in early childhood. 
Being a longitudinal follow-up study design, it can help to clarify the temporal association 
between atopic disorders and the referred mental disorders. 
A previous study65 had found that allergic rhinitis and asthma showed higher risks 
of being associated with ADHD, but the same was not true to AD. Nevertheless, more 
recent evidence enhances the potential relation between AD and ADHD70-72 and ASD72. 
Tsai et al.70 reported higher odds of ADHD for children with AD, allergic rhinitis, asthma 
and allergic conjunctivitis, for both boys and girls, and they also found a correlation 
between the risk of ADHD and the number of atopic disorders. In a Danish nationwide 
population-based cohort study,71 the subjects with a hospital AD diagnosis before the 
age of 15 years presented an HR of 1.3 (95% CI: 1.2-1.5) for an ADHD medication 
requirement and a HR of 1.3 (95% CI: 1.1-1.6) for an ADHD-related admission or 
outpatient clinic visit, comparing to general population controls. Furthermore, receiving 
an AD diagnosis before 2 years of age was associated with an increased HR for ASD by 
10% and for ADHD by 16% in Taiwanese children, wherein the risk of those mental 
conditions increased in case of severe AD and comorbid atopic respiratory diseases.72 
Several studies have shown an impairment in the quality of life of patients living 
with AD, which present more psychological/psychiatric conditions73-75, higher level of 
stress74 and lower productivity73,75. The impact of AD and the associated psychological 
conditions in the overall health of patients is also reflected by the higher prevalence of 
injuries requiring medical attention compared to healthy subjects, which is partly 
mediated by comorbid psychiatric and behavioral disorders.76 
The vast majority of authors propose two main hypotheses to explain the higher 
risk of mental health conditions observed in AD patients. First, the association between 
AD and psychological dysfunction appears to be modified by chronic sleep 
impairment/deprivation59-61,66,70-72,76, which in turn seems closely related with pruritus and 
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consequently scratching overnight. Second, AD and psychiatric diseases may have in 
common some pathogenic factors related to inflammation, with pro-inflammatory 
cytokines being capable of penetrating the blood–brain barrier and activate 
neuropathogenic mechanisms related to emotional control, thus contributing to the 
development of mental health pathology.60,61,69-72,76 Moreover, some researchers also 
suggest the contribution of the negative esthetic aspects of AD lesions and consequent 
stigmatization, which can be significant factors of stress in patients’ social lives.61,64 
Thus, an effective treatment of AD and pruritus may be important measures and 
may have a positive impact in the quality of life of patients. Furthermore, collaboration 
between dermatologists and mental health specialists, as well as treatments targeting 
sleep disturbances, are likely to improve the global health of individuals with AD in 
general, and even more of those with greater risk of developing psychological or 
psychiatric conditions in particular. 
 
 
Conclusions 
  
The growing evidence of potential comorbidities of AD and its systemic immune 
activation reflects the burden of the disease on affected individuals and supports the 
concept of AD as a systemic disease, reinforcing the importance of looking at the 
patient’s overall health, and not only to their skin disease. While various of the referred 
comorbid associations still seem to be unclear and need to be further explored, perhaps 
the immediate main focus should be the improvement of the overall health status of AD 
patients and not only to prove a causality relation between AD and each of those 
presumed associated conditions. 
Patients’ quality of life can be severely compromised by its signs and symptoms, 
so it is important to control the skin disease with the most appropriate treatments. After 
all, it appears that the severity of AD can influence the emergence of various 
comorbidities. Health professionals should work on measures that allow a closer 
surveillance of these patients and should be vigilant in order to prevent and early 
diagnose their comorbidities and their harmful life behaviors. It is fundamental to give 
educational information to the patients and, of course, their families, which are of special 
importance in this disease since it often begins during childhood. Physicians and other 
health professionals who follow these patients should be available to tend to any of their 
needs by caring or referring them to another specialist, given that it is now clear that AD 
is not just a dermatological disease, and that a multidisciplinary approach is essential. 
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